Page last updated: 2024-10-25

citalopram and Parkinson Disease, Secondary

citalopram has been researched along with Parkinson Disease, Secondary in 4 studies

Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.

Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)

Research Excerpts

ExcerptRelevanceReference
"Although we could not establish an association between the anxiety level of rats with either the onset or severity of LID, our results showed that citalopram was able to mediate a partial alleviation in LID after chronic treatment, and the extent of recovery was negatively correlated to the anxiety measures of individual animals."7.74The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram. ( Barker, RA; Kuan, WL; Zhao, JW, 2008)
"Although we could not establish an association between the anxiety level of rats with either the onset or severity of LID, our results showed that citalopram was able to mediate a partial alleviation in LID after chronic treatment, and the extent of recovery was negatively correlated to the anxiety measures of individual animals."3.74The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram. ( Barker, RA; Kuan, WL; Zhao, JW, 2008)

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (75.00)29.6817
2010's1 (25.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Conti, MM1
Ostock, CY1
Lindenbach, D1
Goldenberg, AA1
Kampton, E1
Dell'isola, R1
Katzman, AC1
Bishop, C1
Thwaites, JH1
Hutchinson, C1
Collins, C1
Kuan, WL1
Zhao, JW1
Barker, RA1
Stadtland, C1
Erfurth, A1
Arolt, V1

Other Studies

4 other studies available for citalopram and Parkinson Disease, Secondary

ArticleYear
Effects of prolonged selective serotonin reuptake inhibition on the development and expression of L-DOPA-induced dyskinesia in hemi-parkinsonian rats.
    Neuropharmacology, 2014, Volume: 77

    Topics: Animals; Citalopram; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Acti

2014
Neurotoxic reaction to citalopram.
    The New Zealand medical journal, 2006, Jun-02, Volume: 119, Issue:1235

    Topics: Aged; Basal Ganglia Diseases; Citalopram; Depressive Disorder; Dystonia; Female; Humans; Parkinson D

2006
The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram.
    Psychopharmacology, 2008, Volume: 197, Issue:2

    Topics: Adrenal Cortex Hormones; Amphetamine; Animals; Anxiety; Blotting, Western; Body Weight; Central Nerv

2008
De novo onset of Parkinson's disease after antidepressant treatment with citalopram.
    Pharmacopsychiatry, 2000, Volume: 33, Issue:5

    Topics: Aged; Antidepressive Agents; Citalopram; Depressive Disorder; Female; Humans; Magnetic Resonance Ima

2000